HC Wainwright Reaffirms “Buy” Rating for Agenus (NASDAQ:AGEN)

HC Wainwright reaffirmed their buy rating on shares of Agenus (NASDAQ:AGEN) in a research report report published on Friday, Benzinga reports. HC Wainwright currently has a $40.00 target price on the biotechnology company’s stock.

Several other analysts also recently weighed in on AGEN. B. Riley cut their price objective on shares of Agenus from $120.00 to $100.00 and set a buy rating on the stock in a research report on Monday, March 18th. StockNews.com started coverage on Agenus in a report on Wednesday, April 17th. They set a hold rating on the stock.

Agenus Trading Up 18.6 %

NASDAQ:AGEN opened at $16.75 on Friday. The stock has a 50 day moving average of $13.23 and a 200-day moving average of $12.93. The firm has a market capitalization of $351.75 million, a PE ratio of -1.30 and a beta of 1.35. Agenus has a 52 week low of $4.78 and a 52 week high of $38.60.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($3.04) EPS for the quarter, topping analysts’ consensus estimates of ($3.58) by $0.54. The company had revenue of $28.01 million for the quarter, compared to the consensus estimate of $40.70 million. As a group, analysts predict that Agenus will post -9.7 EPS for the current fiscal year.

Institutional Investors Weigh In On Agenus

Institutional investors have recently bought and sold shares of the stock. PCG Wealth Advisors LLC boosted its stake in Agenus by 65.7% during the 4th quarter. PCG Wealth Advisors LLC now owns 47,550 shares of the biotechnology company’s stock valued at $39,000 after purchasing an additional 18,850 shares in the last quarter. RPO LLC acquired a new position in Agenus during the fourth quarter worth about $43,000. Ables Iannone Moore & Associates Inc. bought a new stake in Agenus in the fourth quarter worth about $65,000. Exchange Traded Concepts LLC lifted its holdings in Agenus by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 107,019 shares of the biotechnology company’s stock valued at $89,000 after acquiring an additional 27,137 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in Agenus in the 4th quarter valued at about $95,000. Institutional investors and hedge funds own 61.46% of the company’s stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.